Advertisement

Drug company deals give markets a shot in the arm

A spate of merger deals between Big Pharma stocks has given the flagging sector a much-needed boost.

It seems the good times are back for Big Pharma. The sector sparked a market rally this week after several companies unveiled mergers and tie-ups worth billions.

Britain's GlaxoSmithKline revealed it would sell its cancer drugs portfolio to Swiss Novartis for around £9.5bn, while buying the Swiss firm's vaccines unit for up to £4.2bn. The two firms will also combine their consumer health business in a join venture.

Advertisement - Article continues below

Novartis is also selling its animal health business in this case, to America's Eli Lilly for $5.4bn. Canada's Valeant Pharmaceuticals made a $47bn cash and stock offer for Botox maker Allergan, supported by Allergan's biggest shareholder, activist investorBill Ackman. The news pushed Allergan's shares up by 15%, while Valeant's rose by 7.5%.

There was also speculation that US giant Pfizer had approached London-listed AstraZeneca about a $100bn takeover which would be the biggest purchase of a UK company ever.

What the commentators said

The Swiss firm is paying seven times forecast 2014 sales and four times peak expected revenues for the unit. But it looks a smart move for GlaxoSmithKline. While looking for cancer cures is "the traditional test of virility for a big drugs group", the failure rate is extremely high.

Mega-deals are often driven by the "Napoleonic ambitions" of executives, said Leonid Bershidsky on Bloomberg View. But in pharma, they make sense. Consultancy McKinsey & Co found that of the 11 pharma groups that remained in the global Top 20 since 1995, seven had made more than $10bn-worth of acquisitions each.

On average, the deals boosted shareholder value, unlike most industries. "In a world where old cash cows are dying off, new breakthrough drugs are few and far between and time to market is longer and longer," expect the consolidation to continue.

Advertisement
Advertisement

Recommended

The British equity market is shrinking
Stockmarkets

The British equity market is shrinking

British startups are abandoning public stockmarkets and turning to deep-pocketed Silicon Valley venture capitalists for their investment needs.
8 Nov 2019
Three biotech stocks on the cutting edge of medicine
Share tips

Three biotech stocks on the cutting edge of medicine

Investors are only now recognising the vast potential of biotech stocks. Here. Professional investor Dr Daniel Koller of BB Biotech AG picks three of …
31 Jul 2019
There are lots of reasons to be bearish – but you should stick with the bulls
Stockmarkets

There are lots of reasons to be bearish – but you should stick with the bulls

There are plenty of reasons to be gloomy about the stockmarkets. But the trend remains up, says Dominic Frisby. And you don’t want to bet against the …
17 Jul 2019
What gold, bonds and tech stocks have in common
Stockmarkets

What gold, bonds and tech stocks have in common

"Risk off" or "safe haven" assets such as gold and government bonds have been doing well lately. But so have riskier tech stocks. That seems to defy c…
10 Jul 2020

Most Popular

OBR: UK house prices could fall by 12% next year
House prices

OBR: UK house prices could fall by 12% next year

The Office for Budget Responsibility says UK house prices could fall by as much as 12% next year. John Stepek looks at how likely that is.
14 Jul 2020
Three ideas for Lloyds Bank's new boss
UK stockmarkets

Three ideas for Lloyds Bank's new boss

The Black Horse needs whipping into shape. A change at the top provides a great opportunity, says Matthew Lynn.
12 Jul 2020
We’re spending more than at any time since World War II – how will we pay it back?
UK Economy

We’re spending more than at any time since World War II – how will we pay it back?

With the UK spending vast sums on stimulus measures, this year’s budget deficit will be greater than at any time since World War II. The big question,…
14 Jul 2020